An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

@article{FerrerSoler2007AnUO,
  title={An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).},
  author={Laura Ferrer-Soler and Alejandro V{\'a}zquez-Mart{\'i}n and Joan Brunet and Javier A. Men{\'e}ndez and Rafael de Llorens and R Colomer},
  journal={International journal of molecular medicine},
  year={2007},
  volume={20 1},
  pages={3-10}
}
Intrinsic resistance to the epidermal growth factor receptor (EGFR; HER1) tyrosine kinase inhibitor (TKI) gefitinib, and more generally to EGFR TKIs, is a common phenomenon in breast cancer. The availability of molecular criteria for predicting sensitivity to EGFR-TKIs is, therefore, the most relevant issue for their correct use and for planning future research. Though it appears that in non-small-cell lung cancer (NSCLC) response to gefitinib is directly related to the occurrence of specific… CONTINUE READING